Advanced Prostate Cancer: Enhancing Combination Therapy

Discover considerations for doublet or triplet therapy in advanced prostate cancer, analyzing the benefits and manageable added toxicity, as discussed by renowned experts in the field.

EP: 1.Optimizing Prostate Cancer Care: A Collaborative Approach

EP: 2.Choosing Partners in Cancer Care: A Strategic Approach

EP: 3.Early-Stage Prostate Cancer Screening and Management Trends

EP: 4.Navigating Prostate Cancer Progression: Risk Assessment and Management

EP: 5.Prostate Cancer Hormone Therapies: A Comprehensive Overview

EP: 6.Enhancing Efficacy in Advanced Hormone-Sensitive Prostate Cancer Treatment

Now Viewing

EP: 7.Advanced Prostate Cancer: Enhancing Combination Therapy

EP: 8.Overcoming Barriers to Triplet Therapy in Prostate Cancer

EP: 9.Advanced Prostate Cancer: Patient Care Continuity

EP: 10.Optimizing Care Collaboration in Advanced Prostate Cancer

Related Videos

Related Content

Advertisement

January 28th 2025

Trial of immune therapy in mCRPC expands enrollment to VA medical center

Hannah Clarke

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 27th 2025

Testosterone therapy and prostate cancer: Risk-benefit and individualized treatment

Mohit Khera, MD, MBA, MPH

“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.

Related Content

Advertisement

January 28th 2025

Trial of immune therapy in mCRPC expands enrollment to VA medical center

Hannah Clarke

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 27th 2025

Testosterone therapy and prostate cancer: Risk-benefit and individualized treatment

Mohit Khera, MD, MBA, MPH

“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.